Axsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) will likely be releasing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $191.3340 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 8:00 AM ET.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $181.21 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The firm’s 50 day moving average price is $170.27 and its 200-day moving average price is $141.61. Axsome Therapeutics has a 52-week low of $86.99 and a 52-week high of $191.50. The company has a market cap of $9.13 billion, a PE ratio of -38.80, a P/E/G ratio of 11.70 and a beta of 0.40.

Wall Street Analyst Weigh In

AXSM has been the subject of a number of analyst reports. Morgan Stanley lowered Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a report on Thursday, January 8th. Jefferies Financial Group boosted their price target on Axsome Therapeutics from $200.00 to $245.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Royal Bank Of Canada upped their price objective on Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Thursday, January 29th. Eighteen investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $210.65.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the transaction, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at $8,003,136.96. This represents a 21.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Herriot Tabuteau sold 32,410 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $185.60, for a total value of $6,015,296.00. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,341,702.40. This trade represents a 81.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 308,874 shares of company stock worth $51,390,805 over the last quarter. Company insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after purchasing an additional 609,516 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after buying an additional 419,008 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Axsome Therapeutics by 831.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after buying an additional 399,000 shares during the period. Marshall Wace LLP grew its holdings in shares of Axsome Therapeutics by 566.5% during the third quarter. Marshall Wace LLP now owns 378,024 shares of the company’s stock valued at $45,911,000 after buying an additional 321,308 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Axsome Therapeutics by 41.1% in the 2nd quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock valued at $78,650,000 after acquiring an additional 219,527 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.